This study compares the image quality and liver lesion detection of using a recently FDA (food and drug administration) approved gadolinium-based contrast agent (GBCA) for magnetic resonance imaging (MRI) called gadopiclenol (Elucirem™) compared to a routinely used gadolinium-based contrast agent (gadoxetate disodium, Eovist™/Primovist™ Bayer Healthcare) for MRI exam of the liver in patients undergoing clinically indicated liver imaging. MRI uses magnetic waves to look at soft tissues in the body.
Additional locations may be listed on ClinicalTrials.gov for NCT06596616.
Locations matching your search criteria
United States
New York
New York
Icahn School of Medicine at Mount SinaiStatus: Active
Contact: Sara Lewis
Phone: 212-824-8475
PRIMARY OBJECTIVE:
I. To compare gadopiclenol MRI to gadoxetate disodium MRI in terms of image quality and liver lesion detection/conspicuity in patients undergoing clinically indicated abdominal MRI in a prospective pilot cross-over study.
OUTLINE: This is an observational study.
Patients undergo contrast-enhanced MRI on study between 1 and 30 days after standard of care MRI.
Trial PhaseNo phase specified
Trial Typescreening
Lead OrganizationIcahn School of Medicine at Mount Sinai
Principal InvestigatorSara Lewis
